NCT03029013

Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

A Phase II Clinical Trial Study on Apatinib and Chemotherapy Sequential Treatment With Advanced Metastatic Cervical Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Third Military Medical University · Academic / Other
• Sex: Female
• Age: 25 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is the single arm and single center clinical trials，We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib and chemotherapy sequential treatment with advanced recurrence of metastatic cervical cancer

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-12-01
• Completion: 2020-12-01
• First posted: 2017-01-23
• Last updated: 2017-01-23

Locations

1 site across 1 country: China